Allergy Therapeutics (LON:AGY) Hits New 12-Month High - Here's Why

Shares of Allergy Therapeutics plc (LON:AGY - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as GBX 8 ($0.11) and last traded at GBX 8 ($0.11), with a volume of 150467 shares. The stock had previously closed at GBX 8 ($0.11).

Allergy Therapeutics Stock Performance

The company has a 50 day simple moving average of GBX 7.07 and a 200-day simple moving average of GBX 6.72. The company has a debt-to-equity ratio of 835.48, a current ratio of 1.63 and a quick ratio of 1.48. The stock has a market cap of £393.21 million, a P/E ratio of -7.71, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY - Get Free Report) last issued its earnings results on Monday, March 31st. The company reported GBX (0.23) ($0.00) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%. On average, equities analysts expect that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.